oxybutynin has been researched along with salmeterol xinafoate in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cianchetta, G; Cruciani, G; Fravolini, A; Giesing, D; Singleton, RW; Vaz, RJ; Wildgoose, M; Zhang, M | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Axelrod, S; Bielory, L | 1 |
| Kawate, E; Mochizuki, H; Nanjo, Y; Takahashi, H; Tsuda, Y; Yamazaki, M | 1 |
| Inoue, H; Ito, I; Iwata, T; Matsumoto, H; Mishima, M; Nagasaki, T; Nakaji, H; Niimi, A; Oguma, T; Otsuka, K; Tajiri, T; Takeda, T | 1 |
2 trial(s) available for oxybutynin and salmeterol xinafoate
| Article | Year |
|---|---|
β2-adrenergic receptor haplotype may be associated with susceptibility to desensitization to long-acting β2-agonists in COPD patients.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Cross-Over Studies; Drug Tolerance; Female; Haplotypes; Humans; Male; Pharmacogenetics; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Receptors, Adrenergic, beta-2; Salmeterol Xinafoate; Terbutaline; Time Factors; Transdermal Patch; Treatment Outcome; Walking | 2012 |
A 12-week, randomized, parallel-group, proof-of-concept study of tulobuterol patch and salmeterol inhaler as add-on therapy in adult-onset mild-to-moderate asthma.
Topics: Adult; Aged; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Salmeterol Xinafoate; Spirometry; Terbutaline; Transdermal Patch | 2017 |
3 other study(ies) available for oxybutynin and salmeterol xinafoate
| Article | Year |
|---|---|
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Fluoresceins; Fluorescent Dyes; Humans; Models, Molecular; Multivariate Analysis; Permeability; Quantitative Structure-Activity Relationship | 2005 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Beta2-agonists and paresthesias in multiple sclerosis.
Topics: Adrenergic beta-Agonists; Albuterol; Amantadine; Analgesics, Non-Narcotic; Androstadienes; Aromatase Inhibitors; Asthma; Bronchodilator Agents; Donepezil; Drug Therapy, Combination; Female; Fluticasone; Food Hypersensitivity; Humans; Indans; Interferons; Latex Hypersensitivity; Letrozole; Mandelic Acids; Middle Aged; Multiple Sclerosis; Nebulizers and Vaporizers; Nitriles; Nootropic Agents; Parasympatholytics; Paresthesia; Piperidines; Respiratory Function Tests; Salmeterol Xinafoate; Thyroxine; Triazoles | 2007 |